Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Roswell Park Cancer Institute
City of Hope Medical Center
Roswell Park Cancer Institute